Office of Clinical Trial of Drug, Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
Guangdong Provincial Key Laboratory of Bone and Joint Degeneration Diseases, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.
J Cell Mol Med. 2020 Jul;24(13):7082-7093. doi: 10.1111/jcmm.15290. Epub 2020 Jun 3.
Stem cell exosomes are nanoscale membrane vesicles released from stem cells of various origins that can regulate signal transduction pathways between liver cells, and their functions in intercellular communication have been recognized. Due to their natural substance transport properties and excellent biocompatibility, exosomes can also be used as drug carriers to release a variety of substances, which has great prospects in the treatment of critical and incurable diseases. Different types of stem cell exosomes have been used to study liver diseases. Due to current difficulties in the treatment of acute liver failure (ALF), this review will outline the potential of stem cell exosomes for ALF treatment. Specifically, we reviewed the pathogenesis of acute liver failure and the latest progress in the use of stem cell exosomes in the treatment of ALF, including the role of exosomes in inhibiting the ALF inflammatory response and regulating signal transduction pathways, the advantages of stem cell exosomes and their use as a drug-loading system, and their pre-clinical application in the treatment of ALF. Finally, the clinical research status of stem cell therapy for ALF and the current challenges of exosome clinical transformation are summarized.
干细胞外泌体是源自各种来源的干细胞释放的纳米级膜囊泡,可调节肝细胞之间的信号转导途径,其在细胞间通讯中的功能已得到认可。由于其天然物质运输特性和优异的生物相容性,外泌体也可用作药物载体来释放各种物质,在治疗危急和不治之症方面具有广阔的前景。不同类型的干细胞外泌体已被用于研究肝脏疾病。由于急性肝衰竭 (ALF) 的治疗目前存在困难,因此本文将概述干细胞外泌体治疗 ALF 的潜力。具体而言,我们综述了急性肝衰竭的发病机制以及干细胞外泌体在治疗 ALF 中的最新进展,包括外泌体在抑制 ALF 炎症反应和调节信号转导途径中的作用、干细胞外泌体的优势及其作为药物加载系统的应用,以及它们在治疗 ALF 中的临床前应用。最后,总结了干细胞治疗 ALF 的临床研究现状和外泌体临床转化的当前挑战。